Showing 81-100 of 258 for: EBMG evidence summaries > Pharmacotherapeutics 
- Cardiovascular risk associated with COX-2 inhibitors
EBMG evidence summaries, 7-Apr-2005
The use of COX-2 inhibitors is associated with a considerably increased risk of cardiovascular events (relative risk in the range of 2–4).
- Celecoxib for rheumatoid arthritis
EBMG evidence summaries, 16-Mar-2007
Celecoxib has similar effect as the traditional NSAIDs for rheumatoid arthritis. It is unclear whether the short-term reduced incidence of upper GI complications are maintained in the long-term.
- Central action beta-blockers for neuroleptic-induced acute akathisia
EBMG evidence summaries, 26-Aug-2007
Beta-blocking drugs are probably not effective for akathisia.
- Choice of antihypertensive drug in the diabetic patient from prognostic point of view
EBMG evidence summaries, 14-Aug-2006
The treatment of hypertension with ACE inhibitors, diuretics, beta blockers and calcium channel blockers improves prognosis in patients with diabetes.
- Cholesterol lowering with statins and risk of stroke
EBMG evidence summaries, 22-Apr-2004
Cholesterol lowering results in a large and significant reduction in the risk of stroke.
- Cholesterol-lowering effect of dietary fiber
EBMG evidence summaries, 20-Mar-2003
Soluble fibre causes a very small but statistically significant reduction in total and LDL cholesterol concentrations.
- Clarithromycin dose in Helicobacter pylori eradication
EBMG evidence summaries, 4-Aug-2003
500 mg of clarithromycin twice daily appears to have been marginally superior to 250 mg twice daily.
- Combination of beta lactam and aminoglycoside antibiotic therapy for sepsis
EBMG evidence summaries, 28-Jul-2006
Adding an aminoglycoside to beta-lactams in the treatment of sepsis does not improve clinical efficacy achieved with the beta-lactam alone. Combination treatment carries a significant risk of nephrotoxicity.
- Combination of inhaled long-acting beta-2 agonists and inhaled steroids versus higher dose of inhaled steroids in persistent asthma
EBMG evidence summaries, 7-Jun-2010
Combination of long-acting beta-2 agonists with inhaled corticosteroids modestly reduces the risk of exacerbations requiring oral corticosteroids, improves lung function and symptoms in adult asthmatics as compared with increasing the dose of inhaled cort
- Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease
EBMG evidence summaries, 19-Sep-2012
Combination of a corticosteroid and a long-acting beta-agonist (budesonide/formoterol or fluticasone/salmeterol) in one inhaler is effective in reducing acute exacerbations and in improving quality of life in adults with chronic obstructive pulmonary dise
- Comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication
EBMG evidence summaries, 8-Apr-2007
There appears to be no difference in the efficacy of different PPIs when used in standard triple therapy for H. pylori eradication.
- Continuous versus intermittent beta-agonists in the treatment of acute asthma
EBMG evidence summaries, 2-May-2011
Continuous nebulized beta-agonists are more effective than intermittent beta-agonists in the treatment of severe acute asthma.
- Corticosteroids for acute bacterial meningitis in adults
EBMG evidence summaries, 2-Dec-2010
Adjuvant corticosteroids appear to reduce hearing loss and might possibly decrease short-term neurological sequelae and mortality in adults with bacterial meningitis.
- Corticosteroids for acute ischaemic stroke
EBMG evidence summaries, 2-Nov-2011
Corticosteroids are probably not effective in the treatment of acute presumed ischaemic stroke.
- Corticosteroids for acute optic neuritis
EBMG evidence summaries, 22-May-2012
There appears to be no long-term benefit of intravenous corticosteroids for the recovery to normal visual acuity, visual field or contrast sensitivity in acute optic neuritis.
- Corticosteroids for acute severe asthma in emergency care and in hospitalised patients
EBMG evidence summaries, 20-Aug-2000
Early emergency treatment of asthma reduces hospitalisations. 60–80 mg per day of methylprednisolone or 300–400 per day mg of hydrocortisone is sufficient to improve lung function in acute severe asthma in hospitalised patients.
- Corticosteroids for acute traumatic brain injury
EBMG evidence summaries, 19-Nov-2009
Corticosteroids are not beneficial in acute traumatic brain injury and may even increase death rate.
- Corticosteroids for children who have ingested a corrosive substance
EBMG evidence summaries, 5-Aug-2003
Corticosteroids appear not to prevent oesophageal injury caused by corrosive substances.
- Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
EBMG evidence summaries, 22-Nov-2012
Corticosteroids seem to have limited effect in the short term in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Standard-dose daily oral corticosteroid (prednisolone) seems to be as beneficial as high-dose oral corticosteroid (dexameth
- Corticosteroids for Guillain-Barré syndrome
EBMG evidence summaries, 22-Nov-2012
Oral corticosteroids appear to slow recovery from Guillain-Barré syndrome. Intravenous methylprednisolone does not produce significant benefit or harm. In combination with IV immunoglobulin, IV methylprednisolone may hasten recovery but does not significa
